Join Precision BioSciences for a virtual investor event featuring Aravindhan Veerapandiyan, MD (Pediatric Neurologist and Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children’s Hospital), and Pat Furlong (Founding President, Parent Project Muscular Dystrophy), who will join Precision leaders to discuss the unmet need, current treatment landscape and PBGENE-DMD for Duchenne muscular dystrophy (DMD), including an overview of the clinical trial design for the FUNCTION-DMD trial.

The event will provide an overview of the Company’s PBGENE-DMD therapy, designed to permanently correct the root genetic cause of DMD by removing a frequently mutated region of the dystrophin gene found in ~60% of patients, restoring the correct reading frame, and enabling natural production of near full-length functional dystrophin. DMD is a genetic disorder resulting in progressive muscle degeneration and early death, affecting skeletal, cardiac, and respiratory muscles. Company management will also discuss plans for the FUNCTION-DMD Phase 1/2 clinical trial following recent U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for PBGENE-DMD. The objective of the FUNCTION-DMD study is to evaluate safety, tolerability, and efficacy, including dystrophin protein expression and functional outcomes in patients afflicted with DMD.

A live question-and-answer session will follow the formal presentations.